Monday, May 21, 2018
 
 
Company News: Page (1) of 1 - 02/14/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
ERLEADA™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer
-- ERLEADA™ is the first FDA-approved therapy to treat patients with non-metastatic castration-resistant prostate cancer-- Approval is based on Phase 3 SPARTAN clinical trial data which showed ERLEADA...
(February 14, 2018)
This article is no longer available,but here are some related topics.


Page: 1


Related Keywords:England,USA,Medicine,Disease,medical technologists,Pregnancy,Cancer,Technology,Surgery,Medication,Womens Health,Pregnancy,Science,Lifestyle,Medical Technology,Medical,Biology,Genetics,Cancer,Science,england,Other,Men,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
  • Global Molecular Diagnostics Markets, 2016-2024 - Focus on Infectious Disease Testing, Blood Screening, Cancer Screening & Other Applications
  • Global Sleep Apnea Diagnostic and Therapeutic Devices Strategic Business Report 2018
  • Global Sleep Apnea Diagnostic and Therapeutic Devices: 2016/18-2024 Strategic Business Analysis & Forecast Report - mHealth-Enabled Sleep Tracking Devices Gain Ground
  • Blavatnik Family Foundation Provides $10 Million Gift to Mount Sinai to Support Mission of Advancing Women’s Health

    Cancer
  • Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.
  • HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage
  • Dr. Haydee Gonzalez Hidalgo joins The Oncology Institute of Hope and Innovation
  • eClinical Solutions Market Size Is Projected To Reach $13 Billion By 2024
  • Multiple New Vendor GPO Awards Position Keneric Healthcare to Increase Its Market Reach for Their Advanced Wound Care and Patient Cleansing Products Lines
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines